# Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial

> **NCT07389980** · PHASE3 · RECRUITING · sponsor: **Yeungnam University College of Medicine** · enrollment: 50 (estimated)

## Conditions studied

- Polypoidal Choroidal Vasculopathy
- Polypoidal Choroidal Vasculopathy (PCV)

## Interventions

- **DRUG:** aflibercept 8 mg

## Key facts

- **NCT ID:** NCT07389980
- **Lead sponsor:** Yeungnam University College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-12-24
- **Primary completion:** 2028-11
- **Final completion:** 2028-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07389980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07389980, "Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07389980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*